Contact Us
Drug Search Results
More Filters [+]

Turoctocog alfa pegol

Alternative Names: turoctocog alfa pegol, esperoct, novoeight
Latest Update: 2024-10-31
Latest Update Note: Clinical Trial Update

Product Description

GlycoPEGylated human recombinant factor VIII (FVIII). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918113/)

Mechanisms of Action: FVIII Analogue

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Colombia | Croatia | Denmark | Germany | Hungary | Israel | Italy | Japan | Netherlands | Norway | Peru | Portugal | Spain | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Turoctocog alfa pegol

Countries in Clinic: Algeria, Argentina, Australia, Austria, Bulgaria, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Malaysia, Romania, Spain, Taiwan, Thailand, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Blood Coagulation Disorders|Hemophilia A|Hemostatic Disorders|Injuries/wounds Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
pathfinder™6

P3

Completed

Hemostatic Disorders|Blood Coagulation Disorders|Hemophilia A

2023-06-07

pathfinder10

P3

Active, not recruiting

Injuries/wounds Unspecified

2023-05-14

Pathfinder10

P3

Completed

Hemophilia A

2022-12-28

JapicCTI-142577

P3

Active

Hemophilia A

2021-11-13

Recent News Events

Date

Type

Title

03/01/2024

PubMed

 Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal.

03/01/2024

PubMed

 Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.

11/17/2023

PubMed

 Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey.

01/16/2023

News Article

 Bleeding Disorder Treatment Market Size is expected to reach at USD 26,177 Million by 2030

04/01/2022

News Article

 Novo Nordisk expands product offerings in Canada for the treatment of Hemophilia A in both children and adults, with availability of ESPEROCT® and ZONOVATE®

03/30/2022

News Article

 Antidiabetics Market Size Estimated to Reach $136 Billion by 2027

02/14/2022

News Article

 Bleeding Disorder Therapeutics Market Size Estimated to Reach $20.7 Billion by 2027

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions